FindTrial
Sign In

Study to Evaluate the Performance of MeRes100 BioResorbable Scaffold in Heart Patients Using CT Angiogram in a single centre

A single-arm, single-centre, observational study to assess the efficacy of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System by CT angiogram in patients with coronary artery disease. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/092735
Enrollment
48
Registered
2025-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I702- Atherosclerosis of native arteriesof the extremities

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Apollo Hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient who has been implanted with MeRes100 BRS. 2. Patient has given written informed consent for participation prior to enrolment. 3. Patient is willing to undergo all study procedures and follow-up requirements

Exclusion criteria

Exclusion criteria: 1. Any condition, which in the Investigator s opinion would preclude safe participation of patient in the study. 2. Patient participating in another clinical investigation

Design outcomes

Primary

MeasureTime frame
Area stenosis Area stenosis is calculated as the reference minus the minimal lumen area as a percentage of the reference lumen area. The reference vessel lumen area is calculated as the average of the mean proximal and mean distal vessel areasTimepoint: 12 month—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Girish Navasundi

Apollo Hospitals

drgirishnavasundi.ct@gmail.com9475414086

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026